Aeterna nach dem Split
diese Woche ***
https://www.nasdaq.com/symbol/aezs/real-time
2.32 0.21 ▲ 9.95% 73,010 $2.11 2.33 / 2.10 $5.57 / $1.29
Data as of 6/12/2019 3:59:30 PM -
https://www.nasdaq.com/symbol/aezs/short-interest
5/31/2019 616,960 87,155 7.078882 §
5/15/2019 674,234 193,463 3.485080 §
4/30/2019 889,587 207,897 4.278979 §
4/15/2019 1,010,083 405,062 2.493650 §
3/29/2019 956,160 284,253 3.363764 §
3/15/2019 957,942 241,391 3.968425 §
2/28/2019 1,240,376 215,475 5.756473 §
2/15/2019 1,394,011 279,817 4.981867 §
1/31/2019 1,319,454 445,755 2.960043 §
1/15/2019 1,039,407 482,360§2.154837
lach!
doch hoffen mit humor ist nicht schlecht! :)
https://www.novonordisk.com/content/dam/Denmark/...agen_Q3%202018.pdf
Wäre schön, wenn Ihr Links ins Forum einbringt, worum es da auch geht, denn die meißten lesen es eh nicht.
So schaut es in der Realität doch aus!
Macrilen ™, das erste und einzige von der FDA zugelassene Produkt zur Diagnose von Wachstumshormonmangel bei Erwachsenen
Translator Google
Seite 4 unter Biopharma
June 13, 2019 Healthcare, Top Market News
Aeterna Zentaris is up 20.69% in midday trading to $2.80. Shares opened today at $2.32. The company has a 52-week low of $1.29 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $5.50, marking a 137.07% potential upside from current levels. In a report issued on May 21, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on AEZS, with a price target of $5.50, which implies an upside of 137% from current levels.